top of page
Logo1.png
  • Blood Borne Viruses
    Hepatitis A Virus (HAV) Hepatitis E Virus (HEV) Parvovirus B19
  • Enteric Viruses and Bacteria
    Clostridium difficile EHEC Norovirus Rotavirus
  • Human Adenovirus, Human Herpesvirus and Polyomavirus
    Human adenovirus (ADV) Cytomegalovirus (CMV) Epstein-Barr Virus (EBV) Human Herpesvirus 6A and 6B (HHV-6) Herpes Simplex Virus 1 and 2 (HSV) Varicella-Zoster Virus (VZV) BK Virus (BKV) JC Virus (JCV)
  • Respiratory Viruses, Bacteria and Fungi
    Human adenovirus (ADV) Enterovirus (ENV) and Rhinovirus (RHV) Human Influenza A and B and SwineFlu Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Human Metapneumovirus A and B (hMPV) Human Parainfluenza Virus 1– 4 (PIV) Respiratory Syncytial Virus A and B (RSVA and RSVB) Bordetella pertussis and Bordetella parapertussis Pneumocystis jirovecii
  • Tropical and other Viruses, Bacteria and Parasites
    AHFV/KFDV CCHFV Chagas Chikungunya Dengue Ebolavirus Filovirus Lassa Virus Malaria Rift Valley Fever Trichomonas vaginalis WNV Yellow Fever Zika Virus

Central Nervous System EQA Programme

  • Arthropod-Borne Viruses

  • BK virus DNA

  • Borrelia burgdorferi spp. DNA

  • Central Nervous System I (Viral Meningitis and Encephalitis)

  • Central Nervous System II (Non-Viral Meningitis and Encephalitis)

  • Herpes simplex virus DNA

  • JC virus DNA

  • Enterovirus RNA

  • Measles and Mumps

  • Toxoplasma gondii DNA

  • Varicella-Zoster virus DNA

  • Parechovirus RNA

In recent years significant advances have been made in understanding CNS pathogenesis with the development of molecular technologies for the diagnosis and monitoring of disease, the introduction of effective treatment therapies and, in some cases, the development of vaccines (e.g. Japanese encephalitis & rabies). The range of QCMD EQA schemes within this area focus on pathogens known to play a significant clinical role in CNS infection. The general aim of this group of EQA schemes is to assess the laboratories’ ability in the detection and determination of the selected pathogen.

​

❮ BACK TO QCMD MAIN

bottom of page